Table 1.
Patient demographics between groups
| Variable | CPB (n = 124) | CPA (n = 122) | p-value |
|---|---|---|---|
| Age (years) | 62.1 ± 7.59 | 62.2 ± 6.84 | 0.183a |
| BMI | 24.5 ± 5.31 | 25.6 ± 6.19 | 0.102a |
| Haemoglobin < 11 g/dLc, n (%) | 36 (29.0) | 32 (26.2) | 0.624b |
| Histology, n (%) | 0.439b | ||
| Squamous | 79 (63.7) | 72 (59.0) | |
| Adenocarcinoma | 34 (27.4) | 37 (30.3) | |
| Adenosquamous | 11 (8.9) | 13 (10.7) | |
| IVB cervical cancer, n (%) | 0.533b | ||
| Asymptomatic CNS metastasis | 45 (36.3) | 49 (40.2) | |
| Without CNS metastasis | 79 (63.7) | 73 (59.8) | |
| Duration of drug (months) | 17.8 ± 7.46 | 17.4 ± 7.63 | 0.219a |
| ECOG status, n (%) | 0.663b | ||
| 0d | 46 (37.1) | 42 (34.4) | |
| 1e | 78 (62.9) | 80 (65.6) | |
| GOG statusf, n (%) | 0.672b | ||
| 0f | 49 (39.5) | 45 (36.9) | |
| 1g | 75 (60.5) | 77 (63.1) | |
| No. of metastatic sites, n (%) | 0.445b | ||
| 3 | 38 (30.6) | 30 (27.8) | |
| > 3 | 71 (57.3) | 78 (62.0) | |
| Unknown | 15 (12.1) | 14 (10.2) |
aAnalysed using an independent samples t-test; bAnalysed using the Mann-Whitney U test;
cHaemoglobin level was calculated one week before the start of CPB or CPA; 0d, Fully active, able to carry on all pre-disease performance without restriction; 1e, Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light housework, office work; 0f: fully active; 1g: restricted in physically strenuous activities, but ambulatory. CPB cisplatin-paclitaxel chemotherapy plus bevacizumab, CPA cisplatin-paclitaxel chemotherapy alone, BMI body mass index, CNS central nervous system, ECOG Eastern Collaborative Oncology Group, GOG Gynecologic Oncology Group